NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
18
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SANDOSTATIN LAR is a long-acting depot formulation of octreotide acetate, a somatostatin analog administered via intramuscular injection. It is indicated for acromegaly, carcinoid syndrome, variceal bleeding, and neuroendocrine tumors by suppressing growth hormone and other peptide hormones. The drug works by binding somatostatin receptors to inhibit hormone secretion and tumor growth.
LOE Approaching
As LOE approaches, brand teams face revenue pressure and may prioritize cost containment, line extension, or transition planning rather than growth investments.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
Started Jul 2014
24 enrolled
Drug Interactions
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Started Nov 2011
256 enrolled
Neuroendocrine TumorsAdvanced Cancer
Effects of Sandostatin LAR® in Acromegaly
Started Oct 2006
21 enrolled
Acromegaly
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Started Sep 2006
70 enrolled
Acromegaly
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Started Mar 2006
20 enrolled
Acromegaly
Worked on SANDOSTATIN LAR at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.